A case of recurrent lung cancer with bone metastases treated with tegafur-uracil and zoledronic acid for long-term survival
Shiono, S.; Harada, M.; Abiko, M.; Sato, T.; Takanashi, I.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 41(6): 757-759
2014
ISSN/ISBN: 0385-0684 PMID: 25129089 Document Number: 671916
We present the case of an 84-year-old man with lumbago due to bone metastases from lung cancer that recurred three years after surgery. The patient received carboplatin-paclitaxel combination as first-line chemotherapy for the treatment of lung cancer, and palliative radiotherapy for the treatment of bone metastases. Gemcitabine was administered as second-line chemotherapy. However, disease progression was observed after three years, and he developed pulmonary metastases. The general condition of the patient worsened, and tegafur-uracil chemotherapy was initiated. Zoledronic acid was also administered. The tegafur-uracil treatment resulted in the disappearance of pulmonary metastases, and a stabilization of the bone metastases. Disease progression was observed after 6 years with a recurrence of pulmonary metastases; however, this did not have a negative impact on the patient's quality of life. Although slow progression may be inherent to lung cancers, it is also possible that the tegafur-uracil and zoledronic acid combination might have contributed to the patient's improved performance.